226 filings
Page 3 of 12
6-K/A
yc9rj40m1fi jsv5q
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
2w27sgi
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
ubz9ewxyob5
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
F-3MEF
44fywo334tey
3 Aug 22
Registration statement to add securities to prior F-3 registration
4:25pm
6-K
74g9rz8b8ewbmch7f
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
xcm06uvw
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
icyxwd nsrk3
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
ehbq33
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
9llp68 9l
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
jrfgjqeg0iaqwrng4t
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
by69a6fp
19 May 22
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
7:05am
6-K
yu8hn7
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
v3gmffdqrd5n0ih47y6t
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
6o2exf 2s4
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
aab27jt4i82 70
7 Apr 22
ObsEva Annual General Meeting 2022
7:01am
6-K
yevydwqy 860ggbqu
31 Mar 22
ObsEva Annual Report 2021
7:05am
6-K
c4wm2ammg
22 Mar 22
Current report (foreign)
7:28am
6-K
m7sy am4dd
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
153 2p8mc0b
3 Mar 22
Prospectus with selling stockholder info
4:43pm